BBV154
Jump to navigation
Jump to search
| Vaccine description | |
|---|---|
| Target | SARS-CoV-2 |
| Vaccine type | Viral vector |
| Clinical data | |
| Routes of administration | Intranasal |
| ATC code |
|
| Part of a series on the |
| COVID-19 pandemic |
|---|
 |
|
.svg){kind=small} COVID-19 portal |
BBV154 is an intranasal COVID-19 vaccine candidate developed by Bharat Biotech.[1][2]
Clinical trials[edit]
Phase I and II trials[edit]
On recommendation by the Subject Expert Committee (SEC) under the Indian drug regulator, the company is going to conduct phase 1 clinical trials using 75 volunteers and submit safety and immunogenicity data for the committee’s consideration before it proceeds to the second phase of the trial.[3]
References[edit]
- ^ Clinical trial number NCT04751682 for "Safety and Immunogenicity of an Intranasal SARS-CoV-2 Vaccine (BBV154) for COVID-19" at ClinicalTrials.gov
- ^ "Intranasal Vaccine For Covid-19". Bharat Biotech. Retrieved 5 March 2021.
- ^ Raghavan P (30 January 2021). "Explained: Understanding BBV154, Bharat Biotech's single-dose intranasal Covid-19 vaccine". The Indian Express.
External links[edit]
 |
Scholia has a profile for BBV154 (Q106309712). |
- Bharat Biotech's Intranasal Vaccine for COVID-19: Everything we know so far about BBV154 firstpost.com
 | This article about vaccines or vaccination is a stub. You can help Wikipedia by expanding it. |
.png){kind=small} | This article about the COVID-19 pandemic is a stub. You can help Wikipedia by expanding it. |